- Home
- LAB
as 07-26-2024 4:00pm EST
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. Its segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas.
Upcoming Earnings Alert:
Get ready for potential market movements as Standard BioTools Inc. LAB prepares to release earnings report on 31 Jul 2024.
| Founded: | 1999 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 939.6M | IPO Year: | 2011 |
| Target Price: | $3.38 | AVG Volume (30 days): | 4.4M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.01 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.57 - $3.16 | Next Earning Date: | 07-31-2024 |
| Revenue: | $126,761,000 | Revenue Growth: | 31.27% |
| Revenue Growth (this year): | 91.08% | Revenue Growth (next year): | 15.52% |
Stock Insider Trading Activity of Standard BioTools Inc. (LAB)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Casdin Partners Master Fund, L.P. | LAB | Director10% Owner | May 23 '24 | Buy | $2.60 | 100,000 | $260,000.00 | 46,075,821 | SEC Form 4 |
| Casdin Partners Master Fund, L.P. | LAB | Director10% Owner | May 20 '24 | Buy | $2.58 | 150,000 | $387,735.00 | 45,975,821 | SEC Form 4 |
| Casdin Partners Master Fund, L.P. | LAB | Director10% Owner | May 20 '24 | Buy | $2.56 | 350,000 | $895,930.00 | 45,825,821 | SEC Form 4 |
| Casdin Partners Master Fund, L.P. | LAB | Director10% Owner | May 20 '24 | Buy | $2.58 | 100,000 | $258,130.00 | 45,475,821 | SEC Form 4 |
| Casdin Partners Master Fund, L.P. | LAB | Director10% Owner | May 15 '24 | Buy | $2.56 | 352,072 | $902,043.67 | 45,375,821 | SEC Form 4 |
| Casdin Partners Master Fund, L.P. | LAB | Director10% Owner | May 15 '24 | Buy | $2.54 | 500,000 | $1,270,950.00 | 45,023,749 | SEC Form 4 |
| Casdin Partners Master Fund, L.P. | LAB | Director10% Owner | May 15 '24 | Buy | $2.57 | 500,000 | $1,282,550.00 | 44,523,749 | SEC Form 4 |
| Casdin Partners Master Fund, L.P. | LAB | Director10% Owner | Mar 4 '24 | Buy | $2.62 | 1,403 | $3,668.85 | 11,497,928 | SEC Form 4 |
| Casdin Partners Master Fund, L.P. | LAB | Director10% Owner | Mar 4 '24 | Buy | $2.57 | 250,000 | $642,500.00 | 11,496,525 | SEC Form 4 |
Latest Standard BioTools Inc. News
LAB Breaking Stock News: Dive into LAB Ticker-Specific Updates for Smart Investing
Simply Wall St.
13 hours ago
Institutional investors must be pleased after a 7.3% gain last week that adds to Standard BioTools Inc.'s (NASDAQ:LAB) one-year returns
GlobeNewswire
10 days ago
Standard BioTools Announces Conference Call and Webcast for Second Quarter 2024 Financial Results on July 31, 2024
Zacks
a month ago
5 Medical Info Systems Stock to Buy for a Stable Portfolio
GlobeNewswire
2 months ago
Standard BioTools Purchases the Carterra® LSA-XT System to Accelerate Data Delivery and Provide Greater Validation to SomaScan Customers
GlobeNewswire
2 months ago
Standard BioTools to Participate in Upcoming Investor Conferences
GlobeNewswire
2 months ago
Standard BioTools Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Insider Monkey
2 months ago
Standard BioTools Inc. (NASDAQ:LAB) Q1 2024 Earnings Call Transcript
Associated Press Finance
3 months ago
Standard BioTools: Q1 Earnings Snapshot
Compare LAB vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "LAB Standard BioTools Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.